Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
-
A4367 Atorvastatin CalciumTarget: HMG-CoA ReductasesSummary: HMG-CoA reductase inhibitor
-
A4368 Safinamide MesylateSummary: MAO-B inhibitor,potent,selective and reversible
-
A4369 Pravastatin sodiumTarget: HMG-CoA ReductasesSummary: HMG-CoA reductase inhibitor,highly selective and competitive
-
A4370 Moclobemide (Ro 111163)Summary: Reversible inhibitor of MAO-A
-
A4371 Ferrostatin-1 (Fer-1)Target: FerroptosisSummary: Ferroptosis inhibitor, erastin-induced
-
A4372 URB597Summary: FAAH inhibitor,potent and selective
-
A4373 NLG9191 CitationSummary: Potent IDO pathway inhibitor
-
A4374 PF-38451 CitationTarget: FAAHSummary: FAAH ihibitor,highly potent and selective
-
A4375 Anacetrapib (MK-0859)1 CitationTarget: CETPSummary: RhCETP/mutant CETP(C13S) inhibitor
-
A4376 Dalcetrapib (JTT-705, RO4607381)Summary: rhCETP inhibitor